Serum soluble RAGE levels and carotid atherosclerosis: The Northern Manhattan Study (NOMAS)

Barry I. Hudson, Hannah Gardener, Wen Liu-Mares, Chuanhui Dong, Ken Cheung, Mitchell S.V. Elkind, Clinton B. Wright, Ralph L. Sacco, Tatjana Rundek

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Background: Recent cohort studies suggested that serum levels of soluble Receptor for Advanced Glycation End-products (sRAGE) are associated with the risk of cardiovascular disease. We hypothesized that sRAGE levels are associated with subclinical atherosclerosis in a racially and ethnically diverse population. Methods and results: 828 stroke-free participants from the Northern Manhattan Study (mean age 71.1±8.7yrs; 64% Hispanic, 19% black, and 17% white) underwent high-resolution carotid B-mode ultrasound to measure carotid plaque (present in 62% of subjects) and intima-media thickness (IMT) (mean Total=0.96±0.10mm). Serum sRAGE was measured by ELISA and associations tested between sRAGE with IMT and plaque presence. Soluble RAGE levels were not associated with plaque presence or IMT after adjusting for sociodemographic, vascular risk factors and medication use. Stratification by race-ethnicity did not reveal any associations with carotid IMT or plaque. Conclusion: In the present study, sRAGE levels were not associated with carotid atherosclerosis.

Original languageEnglish (US)
Pages (from-to)17-20
Number of pages4
Issue number1
StatePublished - May 1 2015
Externally publishedYes


  • Atherosclerosis
  • Biological marker
  • Carotid ultrasound
  • Hispanics
  • IMT
  • Plaque
  • RAGE (receptor for advanced glycation end products)

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Serum soluble RAGE levels and carotid atherosclerosis: The Northern Manhattan Study (NOMAS)'. Together they form a unique fingerprint.

Cite this